Drug intelligence / Profile preview

YB-830

Development stage: Preclinical
Lead developer: Ymmunobio
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YB-830 is a preclinical-stage, neuronal pentraxin receptor (NPTXR)-targeted radioligand therapy (RLT) featuring the beta-emitting radioisotope lutetium-177 ($^{177}\text{Lu}$). Developed by Ymmunobio, the therapeutic is designed to target NPTXR, a tumor-specific marker overexpressed in multiple major solid cancer types (including gastrointestinal and breast cancers) while showing minimal expression in normal tissues. Development activities for YB-830 include pharmacokinetics, target engagement, and organ/tumor dosimetry to evaluate its potential for treating solid tumors.

Targets

NPTXR (Neuronal pentraxin receptor)

Beyond the preview

Go deeper on YB-830.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YB-830.

Explore the full profile